ACA
IBIO icon

Atlas Capital Advisors’s iBio IBIO Stock Holding History

Atlas Capital Advisors’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed -$214 – 994
2022
Q1 		$214 Hold
1
– – ﹤0.01% 897
2021
Q4 		$274 Hold
1
– – ﹤0.01% 913
2021
Q3 		$530 Hold
1
– – ﹤0.01% 914
2021
Q2 		$755 Hold
1
– – ﹤0.01% 910
2021
Q1 		$770 Buy
+1
New +$871 ﹤0.01% 785

Other funds holding IBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Atlas Capital Advisors's IBIO Position: Q2 2022 in Review

Atlas Capital Advisors sold out of iBio (IBIO) in Q2 2022, closing a stake of 1 share — an estimated $214 sold.

Atlas Capital Advisors first reported a position in IBIO in Q1 2021 and held it in 5 quarters. The position peaked at $770 in Q1 2021. 53 funds tracked by Wall St. Rank hold IBIO as of Q2 2022.

  • Atlas Capital Advisors reported no remaining iBio position as of Q2 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 1 iBio share in Q2 2022, an estimated $214.
  • Atlas Capital Advisors first reported a position in iBio in Q1 2021 and held it in 5 quarters.
  • Atlas Capital Advisors's iBio position peaked at $770 in Q1 2021.
  • 53 funds tracked by Wall St. Rank held iBio as of Q2 2022.

Based on Atlas Capital Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.